Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise
Brief Summary: The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise


Options:
A: Arm Label: Metformin alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Glargine followed by Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glargine | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glargine followed by Metformin, Metformin alone | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): Glargine followed by Metformin
B: Arm Label: Saxagliptin 2.5 mg (A); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Saxagliptin 5 mg (B); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Saxagliptin 10 mg (C); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Placebo (D); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matching Saxagliptin, Drug: Metformin | Arm Label: Open-Label Treatment Cohort (Direct Enrollees) (E); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 2.5 mg (A) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 5 mg (B) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 10 mg (C) | Intervention Type: DRUG; Name: Placebo matching Saxagliptin; Assigned to Arm(s): Placebo (D) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Placebo (D) | Intervention Type: DRUG; Name: Placebo matching Metformin; Assigned to Arm(s): Saxagliptin 10 mg (C), Saxagliptin 2.5 mg (A), Saxagliptin 5 mg (B) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Open-Label Treatment Cohort (Direct Enrollees) (E) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Open-Label Treatment Cohort (Direct Enrollees) (E), Placebo (D), Saxagliptin 10 mg (C), Saxagliptin 2.5 mg (A), Saxagliptin 5 mg (B)
C: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
D: Arm Label: 3.0 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 2.0 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 1.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 1.0 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 0.75 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 0.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: 0.25 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo tablet, Drug: Metformin | Arm Label: Sitagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin, Drug: Placebo solution, Drug: Metformin | Arm Label: Placebo/Sitagliptin (Baseline Through 104 Weeks); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo solution, Drug: Placebo tablet, Drug: Metformin | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): 0.25 mg LY2189265, 0.5 mg LY2189265, 0.75 mg LY2189265, 1.0 mg LY2189265, 1.5 mg LY2189265, 2.0 mg LY2189265, 3.0 mg LY2189265 | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Placebo solution; Assigned to Arm(s): Placebo/Sitagliptin (Baseline Through 104 Weeks), Sitagliptin | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): 0.25 mg LY2189265, 0.5 mg LY2189265, 0.75 mg LY2189265, 1.0 mg LY2189265, 1.5 mg LY2189265, 2.0 mg LY2189265, 3.0 mg LY2189265, Placebo/Sitagliptin (Baseline Through 104 Weeks) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 0.25 mg LY2189265, 0.5 mg LY2189265, 0.75 mg LY2189265, 1.0 mg LY2189265, 1.5 mg LY2189265, 2.0 mg LY2189265, 3.0 mg LY2189265, Placebo/Sitagliptin (Baseline Through 104 Weeks), Sitagliptin

Answer: B